According to Latest Report Study, the global autologous cell therapy market is predicted to surpass around USD 34.94 billion by 2030 with a CAGR of 18.13% from 2022 to 2030.
According to Latest Report Study, the global autologous cell therapy market is predicted to surpass around USD 34.94 billion by 2030 with a CAGR of 18.13% from 2022 to 2030.
Autologous Cell Therapy (ACT) is a novel therapeutic intervention that uses an individual’s cells for in-vitro culture and re-introduction into the body. The global ACT market is set out for major growth due to the rise in the number of people suffering from conditions like neurodegenerative disorders, autoimmune disorders, multiple sclerosis, cancer, and so on. These therapies are also used for niche therapeutic utility such as orthopedics and wound healing. Moreover, the rise in the proportion of the geriatric population across the globe coupled with the demand for regenerative medicine, are positively impacting the market growth.
Get the Sample Copy of Report@ https://www.visionresearchreports.com/report/sample/39828
The therapy is intended to replace unhealthy cells with healthy ones mostly by induced expression or the removal of disease causing or dysfunctional cells using immune cells. Advancements in disease biology, coupled with trending technologies such as cell culture, genetic, and protein engineering are conducive to growth of this market. For instance, in December 2021, researchers at the Columbia University Irving Medical Center found out that gene-based cell therapy for SCD restores blood cells to their normal shape and eliminates clinical complications for at least three years.
ACT offer numerous immunological advantages such as eliminating the possibility of graft-versus-host disease (GvHD), which can cause inflammatory symptoms such as enteritis, and dermatitis. They are preferred to achieve Immuno-compatibility for transplantation and also to rule out the need for immunosuppression. Utility of somatic cells for reprogramming into iPSCs to combat Parkinson’s disease. Many studies are underway for using cell therapy to treat Parkinson’s disease. For instance, in May 2022, Aspen Neuroscience plans to advance its lead candidate for Parkinson’s disease and raised USD 147.5 million in Series B financing.
This therapy is being extensively used for devising novel cancer therapeutics and yielded promising outcomes in many studies carried out by researchers across the globe to curb the proliferation of tumorous growth. For instance, in May 2022, Autolus plc presented its research findings at the American Society of Gene & Cell Therapy (ASGCT) about CAR-T cell therapy to treat cancer by using a versatile constitutive cytokine receptor (CCR) system to leverage T cell therapies and to avoid systemic toxicity. Similarly, in April 2022, Autolus Therapeutics plc declares that the U.S. FDA grants an RMAT (Regenerative-Medicine Advanced Therapy) designation for its CAR-T cell therapy called obecabatagene autoleucel (intended for use in the treatment of acute lymphocytic leukemia) that is now undergoing Phase-II trial.
Advantages include the minimization of risks from bio-incompatibility, and disease transmission risks associated with grafts and are therefore used to bioengineer skin substitutes, aid wound healing, reversal of chronic inflammation, treat ulcers, and leverage postoperative healing. There are many corporate developments in terms of acquisitions and expansions to effectively market wound healing technologies. For instance, in June 2022, Switzerland based company, Healiva acquired two innovative cell therapy assets, EpiDex and Healiva002 from Smith+Nephew so as to establish a broad spectrum of personalized wound care by comprehensive use of enzyme technology, ACT, and associative medical devices.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39828
However, hassles in harvest processes, the logistic intricacies (involving clinical procedures) are hindrances to the growth of the market. It is crucial that the procedures are well-timed and coordinated to mitigate the risk of cross-contamination. Turnaround time of several weeks can make the option not favorable in cases where clinicians are making a last attempt to save the life of a patient.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 7.8 billion |
| Revenue Forecast by 2030 | USD 34.94 billion |
| Growth rate from 2022 to 2030 | CAGR of 18.13% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Source, Application, End-Use, Region |
| Companies Covered | BrainStorm Cell Therapeutics, Holostem Terapie Avanzate S.R.L, Lineage Cell Therapeutics Inc., Pharmicell Co. Inc, Opexa Therapeutics, Caladrius Biosciences Inc, Castle Creek Biosciences Inc, Regeneus Ltd., Opexa Therapeutics Inc, Takeda Pharmaceutical Company Limited, U.S. Stem Cell Inc, and Vericel Corporation |
Key Market Trends
Musculoskeletal Disorder Segment is Expected to Hold the Largest Market Share in the Autologous Cell Therapy Market
The musculoskeletal disorders segment is expected to drive the demand for autologous cell therapy for effective treatment. The rise in musculoskeletal disorders among the global population is expected to contribute to the growth of the studied segment along with the launch of innovative autologous cell therapies.
The Key facts published by World Heart Organization (WHO) in February 2021 reported that about 1.71 billion people have musculoskeletal conditions worldwide. Musculoskeletal conditions are the leading contributor to disability worldwide, with low back pain being the single leading cause of disability in 160 countries. Among musculoskeletal disorders, low back pain causes the highest burden with a prevalence of 568 million people. According to the same source, the aging population in the world is increasing, and the number of people with musculoskeletal conditions is rapidly increasing. Musculoskeletal conditions are also the biggest contributor to years lived with disability (YLDs) worldwide with approximately 149 million YLDS, accounting for 17% of all YLDs worldwide. Thus, the increasing number of musculoskeletal disorders is expected to increase the need for effective therapies such as autologous therapies, thereby contributing to the growth of the market.
Also, according to Work-Related Musculoskeletal Disorders statistics in Great Britain, in 2021, 470,000 people suffer from work-related musculoskeletal disorders which are new or long-standing in the year 2020-2021. In the future, such incidence of musculoskeletal disrders conditions are expected to drive the demand for effective therapies which will accelerate the segment growth in the forecast period.
Key Players
- BrainStorm Cell Therapeutics
- Holostem Terapie Avanzate S.R.L
- Lineage Cell Therapeutics Inc.
- Pharmicell Co. Inc
- Opexa Therapeutics
- Caladrius Biosciences Inc
- Castle Creek Biosciences Inc
- Regeneus Ltd.
- Opexa Therapeutics Inc
- Takeda Pharmaceutical Company Limited
- U.S. Stem Cell Inc
- Vericel Corporation.
Market Segmentation
- By Source
- Bone Marrow
- Epidermis
- Mesenchymal stem cells
- Haematopoietic stem cells
- Chondrocytes
- Others
- By Application
- Cancer
- Neurodegenerative disorders
- Cardiovascular disorders
- Autoimmune disorders
- Orthopaedics
- Wound healing
- Others
- By End-Use
- Hospitals & Clinics
- Academics & Research
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39828
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/